医学
前列腺癌
生长抑素受体
下调和上调
雄激素受体
癌症研究
前列腺
尿激酶受体
表观遗传学
神经内分泌肿瘤
腺癌
疾病
Pet成像
病理
跨膜蛋白
受体
雄激素
癌症
核医学
雄激素剥夺疗法
疾病监测
神经内分泌分化
作者
Akshay Bedmutha,Bruce Barron,Stephen Lau,Kyle Oi,David Brandon
标识
DOI:10.1097/rlu.0000000000006182
摘要
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer, often developing from androgen receptor (AR) independence, characterized by neuroendocrine molecular markers and nonresponsiveness to standard treatments of prostate adenocarcinoma. The evolution of adenocarcinoma to NEPC is characterized by epigenetic changes, leading to the downregulation of the PSMA transmembrane protein, as well as the upregulation of FDG-uptake pathways and somatostatin receptor expression. We present a case of NEPC that depicts a significant metastatic intertumoral heterogeneity as depicted on PSMA, FDG, and DOTATATE PET/CT scans. Such multiprobe PET evaluation of NEPC may assist in sampling the most aggressive disease and guide an appropriate management strategy. It also provides a cellular-level insight into this dreadful disease with very limited treatment options.
科研通智能强力驱动
Strongly Powered by AbleSci AI